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A B S T R A C T   
Introduction: Inflammation is a normal physiological process that increases to harmful levels in preeclampsia. It 
affects the interaction between maternal immune cells and fetal trophoblasts at both sites of the maternal-fetal 
interface; decidua and placenta. The pattern recognition receptor nucleotide-binding oligomerization domain- 
containing protein (NOD)1 is expressed at both sites. This study aimed to characterize the cellular expression 
and functionality of NOD1 at the maternal-fetal interface of normal and preeclamptic pregnancies. 
Methods: Women with normal or preeclamptic pregnancies delivered by caesarean section were included. 
Decidual (n = 90) and placental (n = 91) samples were analyzed for NOD1 expression by immunohistochemistry 
and an automated image-based quantification method. Decidual and placental explants were incubated with or 
without the NOD1-agonist iE-DAP and cytokine responses measured by ELISA. 
Results: NOD1 was markedly expressed by maternal cells in the decidua and by fetal trophoblasts in both decidua 
and placenta, with trophoblasts showing the highest NOD1 expression. Preeclampsia with normal fetal growth 
was associated with a trophoblast-dependent increase in decidual NOD1 expression density. Compared to normal 
pregnancies, preeclampsia demonstrated stronger correlation between decidual and placental NOD1 expression 
levels. Increased production of interleukin (IL)-6 or IL-8 after in vitro explant stimulation confirmed NOD1 
functionality. 
Discussion: These findings suggest that NOD1 contributes to inflammation at the maternal-fetal interface in 
normal pregnancies and preeclampsia and indicate a role in direct maternal-fetal communication. The strong 
expression of NOD1 by all trophoblast types highlights the importance of combined assessment of decidua and 
placenta for overall understanding of pathophysiological processes at the maternal-fetal interface.   
1. Introduction 
Direct maternal-fetal interaction during pregnancy occurs in the 
uterine wall decidua and at the placental surface facing maternal blood. 
These sites are closely interconnected and adapted to allow maternal 
cells to directly interact with specialized fetal trophoblasts. In the 
decidua, extravillous trophoblasts facilitate remodeling of the spiral 
arteries and remain in close interaction with tissue resident maternal 
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immune cells throughout pregnancy [1,2]. In the placenta, the multi-
nucleated syncytiotrophoblast layer that covers the fetal placental 
structures is directly exposed to immune cells in the circulating maternal 
blood [3]. These two delicate maternal-fetal interaction sites are sensi-
tive to perturbations of both exogenous and endogenous origin, and 
untimely inflammatory triggers can induce a harmful immune activation 
during pregnancy [3,4]. 
A low-grade inflammation at the maternal-fetal interface represents 
the body’s physiological adaptation to pregnancy and is characterized 
by controlled production of cytokines and angiogenic factors by tro-
phoblasts and maternal immune cells [5–7]. The corresponding 
maternal systemic inflammation is associated with leukocytosis and 
enhanced cytokine production by circulating maternal immune cells 
upon their interaction with the placental syncytiotrophoblast and acti-
vators released from the placenta [3]. The inflammatory pregnancy 
disorder preeclampsia manifests as maternal hypertension with pro-
teinuria and/or organ dysfunction after 20 weeks of gestation. It affects 
2–8% of pregnancies and can be further complicated by fetal growth 
restriction (FGR) [8,9]. Preeclampsia is characterized by exaggerated 
inflammation with increased production of inflammatory cytokines both 
at the maternal-fetal interface and in the maternal circulation [6,10]. 
This harmful inflammation is associated with deficient spiral artery 
remodeling in the decidua and subsequent altered uteroplacental 
perfusion causing hemodynamic, oxidative, and endoplasmic reticulum 
(ER) stress in the placenta. As the pregnancy progresses, the dysfunc-
tional placenta releases increasing amounts of danger signals to the 
maternal circulation, thereby eliciting maternal systemic inflammation, 
endothelial dysfunction and symptomatic preeclampsia [11,12]. 
Inflammation is initiated when the innate immune system recognizes 
danger signals through pattern recognition receptors (PRRs). Both 
maternal immune cells and trophoblasts express PRRs, enabling them to 
communicate with each other and respond to their surroundings [5]. 
When dysregulated at the maternal-fetal interface, PRR activation may 
disrupt the delicate immunological environment, and we have previ-
ously identified a role for Toll-like receptor 3 and 4 and Nod-like re-
ceptor protein (NLRP)3 in the development of preeclampsia [13–16]. 
Nucleotide-binding oligomerization domain-containing protein (NOD) 
1 is an intracellular PRR that responds to endogenous stress signals or 
invading pathogens [17]. Aberrant NOD1 expression and function are 
associated with inflammatory bowel disease, metabolic syndrome and 
cancer [18–20]. The receptor is ubiquitously expressed [21,22] and was 
first established as a sensor of bacterial peptidoglycan (γ-D-gluta-
myl-meso-diaminopimelic acid (iE-DAP)) [23–25]. More recent studies 
have shown that endogenous danger signals derived from ER stress and 
saturated fatty acids also can elicit NOD1 signaling, but the exact 
mechanisms of activation have not been determined [26–28]. Activation 
of NOD1 culminates in the production of inflammatory cytokines 
through NF-κB and MAPK signaling pathways [29,30]. 
NOD1 is expressed in the decidua and placenta and mounts an in-
flammatory response to specific danger signals [31–39]. Aberrant NOD1 
expression has been associated with the pregnancy complications 
miscarriage, premature rupture of membranes, preterm labor and 
gestational diabetes [31,34,38–40] and we have previously shown dif-
ferential decidual gene expression of NOD1 in preeclampsia [41]. In 
mice, activation of NOD1 has been associated with preterm labor, FGR 
and intrauterine fetal death [36,42], as well as augmented inflammation 
in the mother and fetus [36]. The full role of NOD1 in the delicate 
interplay between maternal and fetal cells at the maternal-fetal interface 
remains largely unknown as previous studies have been small, focused 
on infections, and separately assessed either the decidua or the placenta. 
In this study, we aimed to determine the inflammatory role of NOD1 at 
the maternal-fetal interface in normal and preeclamptic pregnancies 
through characterization of the cellular expression and functionality of 
NOD1 in the decidua and placenta. 
2. Methods 
2.1. Ethical approval 
This study was approved by the Norwegian Regional Committee for 
Medical and Health Research Ethics as part of the Preeclampsia Study 
(approval no. 2012/1040) and the First and Third Trimester Study 
(approval no. 2009/3). Informed written consent was obtained from all 
participants. 
2.2. Study population 
The Preeclampsia Study includes healthy and preeclamptic singleton 
pregnancies delivered by caesarean section (CS) in absence of labor at 
St. Olavs and Haukeland University Hospitals between 2002 and 2012. 
Pregnant women diagnosed with preeclampsia with or without FGR 
were included as cases. Healthy normotensive pregnant women with no 
previous history of preeclampsia or FGR were included as normal 
pregnant controls. Decidua basalis tissue was collected by vacuum 
aspiration of the placental bed during CS [43,44], and a placental biopsy 
was taken tangentially from the central part of the maternal side of the 
placenta shortly after delivery in a standardized manner. The tissue 
samples were fixed in 10% neutral-buffered formalin and embedded in 
paraffin for immunohistochemical analyses. 
Preeclampsia was defined as persistent hypertension (systolic/dia-
stolic blood pressure > 140/90 mmHg) and proteinuria (>300mg/24 h 
or > 1+ by dipstick) developing after 20 weeks of gestation. Women 
with pre-gestational hypertension developing proteinuria in the second 
half of pregnancy were diagnosed with superimposed preeclampsia and 
included in the preeclampsia group. FGR was determined by serial ul-
trasound measurements showing reduced intrauterine growth or, for 
neonates small for gestational age (n = 1), birth weight < 5th percentile 
of Norwegian reference curves [45] combined with clinically and 
sonographically suspected FGR and/or postpartum defined placental 
pathology. 
The First and Third Trimester Study includes women with normal 
singleton pregnancies delivered by CS at St. Olavs University Hospital 
between 2015 and 2017. Third trimester placentas were collected after 
delivery for immediate isolation of decidual and placental explants and 
used for stimulation assays. 
2.3. Immunohistochemistry and quantitative protein expression 
Serial decidual and placental tissue sections of 3 μm were pre-treated 
in PT link (#PT101, Dako) using target retrieval solution (#K8005 or 
#K8004, Dako) at 97 ◦C for 20 min, and next treated with peroxidase 
blocking solution (#K4007 or #K5361, Dako). The tissue sections were 
incubated with primary antibodies for NOD1 (decidua 1:50, placenta 
1:150, #MAB7090, R&D Systems, overnight at 4 ◦C); cytokeratin 7 
(CK7) (decidua 1:300 for 45 min, placenta 1:800 for 40 min, #M0851, 
Dako, room temperature); CD31 (1:50, #M0823, Dako, room tempera-
ture for 40 min); or CD45 (1:150, #M0701, Dako, room temperature for 
40 min). All sections were incubated for 30 min with HRP-labeled 
polymer (#K4007, Dako) and for 10 min with DAB+ as chromogen 
(1:50, #K4007 or K5361, Dako). Decidual CK7 sections were double 
stained with smooth muscle actin antibodies (1:300, #M0851, Dako) 
using EnVision G|2 Doublestain System Rabbit/Mouse (DAB+/Perma-
nent Red) Kit system (K#5361, Dako). Stainings were performed by 
Autostainer Plus (#S3800, Dako) or manually for overnight stainings. 
Sections were counterstained with hematoxylin. Negative isotype con-
trols for NOD1 were included (decidua 1:1.25, placenta 1:5, Mouse IgG1 
#349040, BD Pharmigen). Additional routine staining with hematoxylin 
(75290, Chemi-Teknik AS), erythrosine 239 (720–0179, VWR) and 
saffron (75100, Chemi-Teknik AS) (HES) was performed using a Sakura 
Tissue-Tek © Prisma StainerTM (Sakura Finetek). 
To ensure a representative analysis, large tissue section scans were 
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obtained by the EVOS™ FL Auto Imaging System (Thermo Fisher Sci-
entific) by combining between 4 and 81 (decidua) and 9–36 (placenta) 
adjacent bright field TIFF images for each donor (20X magnification, 
2048× 1536 pixels) depending on the amount of available tissue. A 
custom ImageJ script was used to perform background correction and 
tile stitching [46–48]. The large scans were further analyzed by 
tissue-specific MATLAB scripts (version 2017b, The MathWorks, Inc.) 
developed for identification and automated quantification of staining 
density and intensity, as previously described by Gierman et al. [13] and 
Silva et al. [16]. Protein expression was quantified in one large tissue 
section scan for each decidua and placenta with the examiner blinded to 
pregnancy outcome. 
2.3.1. Quantitative decidual protein expression 
Decidual areas with smooth muscle tissue, placental tissue, blood 
vessels, endometrial glands and tissue with poor aberrant morphology 
were excluded by manually defining regions of disinterest. A mask of 
square patches (100 x 100 pixels, 1325 μm × 1325 μm) defining tro-
phoblasts and maternal tissue without trophoblasts was created for each 
decidua based on CK7 positive staining. The created masks were used to 
relate NOD1 expression to trophoblasts and maternal tissue in the 
spatially aligned NOD1 tissue scans. The decidual NOD1 expression den-
sity was calculated as the total number of NOD1 positive pixels divided 
by the total amount of tissue pixels analyzed (pixels per patch x number 
of patches) to account for varying amounts of tissue between the sam-
ples. The decidual NOD1 expression intensity was calculated as the 
average intensity value of all positive patches using a color deconvolu-
tion algorithm based on DAB-specific RGB absorption [49]. NOD1 
expression intensity was further analyzed according to the presence of 
trophoblasts in the decidua, ranging from 0% to 100% trophoblast 
coverage (based on the percentage of CK7 positive pixels). Trophoblasts 
were automatically counted, and the trophoblast density was calculated 
as the total number of trophoblasts divided by the total area of tissue 
(mm2). 
2.3.2. Quantitative placental protein expression 
Placental areas with stem villi, decidual tissue and tissue with poor 
aberrant morphology were excluded by defining regions of disinterest. 
The images were analyzed by binary masks created by segmentation 
based on RGB color values using the color threshold app in MATLAB. 
The cells positively stained for NOD1 were used as reference points to 
create a mask selecting only NOD1 positive pixels, and the NOD1 
expression density in placental villi was quantified as the total number of 
NOD1 positive pixels divided by the total number of tissue image pixels. 
The NOD1 expression intensity in placental villi was measured as the 
average intensity in a mask selecting only the tissue and not the inter-
villous space. Placental NOD1 expression intensity was further quanti-
fied and related to trophoblasts by creating a mask selecting the 
syncytiotrophoblast layer and underlying cytotrophoblasts by using the 
syncytiotrophoblast layer of each individual placenta as reference point. 
The NOD1 expression intensity values were measured as gray-level in-
tensity values ranging from 0 (absence of color, black) to 255 (presence 
of all colors, white) after conversion from RGB to grayscale images. 
Staining intensity is therefore inversely proportional to the protein 
expression level, and the intensity values were subtracted from 255 to 
obtain a direct proportional relation to protein expression. 
2.4. Decidual and placental explants 
Third trimester placentas were processed within 2 h and 45 min after 
delivery. Healthy-looking cotyledons were dissected from the central 
region of the maternal side of the placenta. From these cotyledons; 
decidual tissue was isolated by removing the fetal membranes and 
placental villous tissue; and placental tissue was isolated by removing 
the fetal membranes and decidual tissue. The resulting tissue was 
washed in sterile phosphate-buffered saline and cut into pieces 
(explants) of similar weight (26.3 ± 5.0 mg (decidua) and 24.7 ± 4.6 mg 
(placenta)). Explants were cultured in Ham’s F12/Dulbecco’s modified 
Eagle’s medium with 10% fetal bovine serum and 100 mg/mL penicillin- 
streptomycin (Sigma-Aldrich) and incubated for 24 h at 37 ◦C, 8% O2 
and 5% CO2 [50]. Culture medium was then replaced with fresh culture 
medium with or without iE-DAP (NOD1-agonist, 10 μg/mL, #tlrl-dap, 
InvivoGen) or iE-lys (NOD1-antagonist, 10 μg/mL, #tlrl-lys, InvivoGen). 
Supernatants were collected after 24 h, centrifuged and stored at 
− 80 ◦C. For further analysis, six technical replicates for each experi-
mental condition were combined. Tissue viability was assessed by 
lactate dehydrogenase cytotoxicity assay (#04744926001, Roche), 
confirming that the stimuli had no toxic effect. Interleukin (IL)-6 and 
IL-8 in supernatants from decidual and placental explants (diluted 1:500 
and 1:1000, respectively) and interferon-γ-inducible protein-10 (IP-10) 
from placental explants (diluted 1:10) were measured in duplicate using 
quantitative sandwich ELISA (#DY206, #DY208, #DY266, R&D 
Systems). 
2.5. Statistical analyses 
Statistical analyses were performed in SPSS (IBM SPSS Statistics 25) 
and GraphPad Prism (Prism8). For clinical data, one-way ANOVA or 
Kruskal-Wallis with Tukey’s or Dunn’s test, respectively, were used for 
comparisons of continuous variables, and Fisher’s exact test for cate-
gorical variables. Protein measurements in supernatants were analyzed 
by one-way ANOVA with Dunnet’s test or Kruskal-Wallis with Dunn’s 
test. For the immunohistochemistry data, the amount and density of 
decidual trophoblasts were compared between study groups by one-way 
ANOVA with Tukey’s test for pairwise comparisons. The overall protein 
expression of NOD1 in decidua and placenta was evaluated by a linear 
regression model with recruitment location and study group as addi-
tional covariates. For normal pregnancies, NOD1 expression in placental 
villi was compared to the NOD1 expression in the syncytiotrophoblast 
and cytotrophoblasts by a linear mixed model with expression location 
as fixed effect variable. In all linear mixed models, within-subject cor-
relations were accounted for by including a subject-specific random 
intercept. To analyze decidual NOD1 expression levels according to the 
number of trophoblasts, average intensity values for each patch were 
included in the statistical analyses. Trophoblast coverage were either 
included as average percentage for each patch, ranging from 0% to 
100% (continuous variable) or grouped into intervals of 0%, >0–50% 
and >50% trophoblast density (categorical variable). To compare NOD1 
expression in maternal tissue (0% trophoblasts) and trophoblast- 
containing tissue (>0–50 or >50% trophoblasts), a linear mixed 
model with recruitment location and trophoblast density interval as 
fixed effects variables was used. NOD1 expression levels were further 
compared between the study groups using a linear mixed model with 
recruitment location, study group and the interaction between study 
group and percentage of trophoblast coverage and the percentage of 
trophoblast coverage in each patch implemented as fixed effects vari-
ables. The significance level was set to 0.05. 
3. Results 
3.1. Clinical characteristics of study subjects 
Of the 122 pregnancies included from the Preeclampsia Study, two 
decidual and five placental samples were excluded due to poor tissue 
morphology or methodological problems (immunohistochemical stain-
ing or image analysis). The remaining 119 pregnancies were included 
with decidual (n = 90) and placental (n = 91) samples, some of which 
had both tissue types (n = 62). The decidual analyses included women 
with normal pregnancies (n = 44), preeclampsia without FGR (n = 19) 
and preeclampsia with FGR (n = 27); the placental analyses included 
women with normal pregnancies (n = 43), preeclampsia without FGR (n 
= 22) and preeclampsia with FGR (n = 26); and the combined decidual 
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and placental analyses included women with normal pregnancies (n =
29), preeclampsia without FGR (n = 16) and preeclampsia with FGR (n 
= 17). As expected, women who developed preeclampsia had higher 
systolic and diastolic blood pressure, more were primiparas, and their 
infants were delivered at earlier gestation with lower placenta and birth 
weights when compared to normal pregnancies (Table 1). The gesta-
tional age at delivery as well as placenta and birth weights were lower in 
preeclamptic pregnancies complicated with FGR compared to pre-
eclamptic pregnancies without FGR (Table 1). 
Tissue from nine normal third trimester pregnancies with gestational 
age range 38–41 weeks was used for isolation of either decidual or 
placental explants. 
3.2. Cellular composition at the maternal-fetal interface 
The decidual tissue consisted of decidualized endometrial stroma 
cells, maternal leukocytes (CD45+) and extravillous trophoblasts 
(CK7+), as well as smooth muscle tissue (smooth muscle actin+) and 
extracellular matrix components (Fig. 1A–F). Trophoblasts were clus-
tered together surrounded by fibrinoid tissue or appeared as single cells 
closely connected to maternal leukocytes and decidual stroma cells. 
Both mononucleated extravillous trophoblasts and multinucleated 
trophoblast giant cells were identified (Fig. 1A–F and [13]). The 
placental sections showed numerous villous structures, predominantly 
mature intermediate and terminal villi, but also some larger stem villi 
and a few immature villi (Fig. 1G-L). All villous structures were covered 
by the multinucleated syncytiotrophoblast layer and underlying cyto-
trophoblast cells (CK7+). The core of the villi contained fetal endothelial 
cells (CD31+), fibroblasts and leukocytes (CD45+) (Fig. 1G-L). 
3.3. Decidual and placental expression and function of NOD1 in normal 
pregnancies 
NOD1 was expressed by multiple cells of both fetal and maternal 
origin in the decidua (Fig. 1E). NOD1 was strongly expressed in the fetal 
mononucleated extravillous trophoblasts and multinucleated tropho-
blast giant cells. Maternal decidual stroma cells, leukocytes and smooth 
muscle cells showed a moderate expression of NOD1. When quantified 
according to fetal and maternal cells, the intensity of NOD1 expression 
increased with increasing presence of trophoblasts in the decidua 
(Fig. 2A). In the placenta, NOD1 was markedly expressed in the syncy-
tiotrophoblast layer and cytotrophoblasts of placental villi (Fig. 1K) and 
a weaker expression of NOD1 was located to fetal leukocytes and around 
fetal vessels. The intensity of NOD1 expression was significantly higher 
in the syncytiotrophoblast layer and underlying cytotrophoblasts 
compared to in placental villi as a whole (Fig. 2B). 
Explant stimulation confirmed NOD1 activity at the maternal-fetal 
interface. The NOD1-agonist iE-DAP induced a significantly increased 
release of IL-8, but not IL-6, in decidual explants (Fig. 3A and B). NOD1 
activation of placental explants induced a significantly increased release 
of IL-6 and IL-8 (Fig. 3C and D), but not IP-10 (data not shown). Viability 
assessment confirmed that the stimuli had no toxic effects in any of the 
culture conditions (Fig. S1). 
3.4. Overall NOD1 expression at the maternal-fetal interface comparing 
normal and preeclamptic pregnancies 
The cellular localization of NOD1 was comparable and the amount 
and density of decidual trophoblasts did not differ between normal and 
preeclamptic pregnancies (data not shown). Quantification of the 
overall decidual NOD1 expression showed a significantly higher NOD1 
density (Fig. 4A) (P = 0.041) and a tendency towards stronger NOD1 
intensity (Fig. 4B) (P = 0.079) in preeclamptic pregnancies with normal 
fetal growth compared to normal pregnancies. The overall placental 
NOD1 expression did not differ between normal and preeclamptic 
pregnancies (Fig. 4C and D). Summary of the results are shown in 
Table S1 for decidua and Table S2 for placenta. 
We further investigated whether decidual and placental NOD1 
expression intensity was regulated in the same manner within each 
pregnancy. Interestingly, the decidual-placental correlation of NOD1 
expression intensity diverged across the diagnostic groups. NOD1 
showed a weak decidual-placental correlation in normal pregnancies (r 
= 0.4), whereas this correlation was markedly stronger in preeclamptic 
pregnancies with (r = 0.6) and without (r = 0.7) FGR. 
3.5. Cellular NOD1 expression in the decidua comparing normal and 
preeclamptic pregnancies 
NOD1 expression intensity in the heterogenous decidual tissue was 
further related to trophoblasts and maternal cells. Decidual NOD1 in-
tensity markedly increased with increasing presence of trophoblasts 
both in normal and preeclamptic pregnancies (Fig. 5). In decidual tissue 
with high amounts of trophoblasts (>48%), NOD1 intensity was 
significantly higher in preeclamptic pregnancies with normal fetal 
growth compared to normal pregnancies (Fig. 5). The NOD1 expression 
intensity did not differ between normal and preeclamptic pregnancies in 
decidual tissue with only maternal cells (0% trophoblasts) (Fig. 5). 
4. Discussion 
This study demonstrated that NOD1 is strongly expressed by all types 
of trophoblasts across the maternal-fetal interface and moderately 
expressed by maternal cells in the decidua. Preeclamptic pregnancies 
showed stronger correlation between decidual and placental NOD1 
expression, and preeclampsia with normal fetal growth was associated 
with a trophoblast-dependent increase in decidual NOD1 expression 
Table 1 
Clinical characteristics of subjects included in third trimester decidual and 
placental analyses (n = 119).   
Normal pregnancies 
(n = 58) 
PE1 without 
FGR (n = 25) 
PE with FGR 
(n = 36) 
Baseline characteristics 
Maternal age, years 31.4 (±5.3) 29.8 (±4.9) 30.4 (±5.7) 
Primiparas, n (%)a 11 (19) 15 (60)* 19 (53)* 
BMIb 24.9 (±4.0) 26.4 (±6.1) 26.4 (±4.6) 
Characteristics at time of delivery 
Systolic BP, mmHgc 119.3 (±11.1) 166.3 (±19.3)* 158.7 (±16.6) 
* 
Diastolic BP, mmHgc 72.7 (±8.8) 101.6 (±12.3)* 98.8 (±9.2)* 
Gestational age, 
weeks 
38.6 (±0.8) 32.8 (±3.6) * 30.6 (±3.2) 
*,** 
Severe PE2, n (%) n.a. 21 (84) 25 (69) 
Early onset PE < 34 
weeks, n (%) 
n.a. 20 (80) 30 (83) 
Placental weight, gd 610 (183) 420 (225)* 274 (100)*,** 
Fetal birth weight, g 3490 (517) 2070 (820)* 1152 (698) 
*,** 
PE; preeclampsia; FGR, fetal growth restriction; BMI, body mass index; BP, blood 
pressure; n.a., not applicable; n.s., not significant. 
Continuous variables listed as means (±standard deviation) or median (inter-
quartile range), assessed for differences between groups by one-way ANOVA 
with Tukey’s post hoc test or Kruskal-Wallis with Dunn’s post hoc test. Cate-
gorical variables listed as number (percent in column), assessed for differences 
between groups by Fisher’s exact test. 
*P < 0.05 vs normal pregnancies. **P < 0.05 vs PE without FGR. 
1 Six of the women included as preeclamptic were diagnosed with superimposed 
PE. 2 PE was sub-phenotyped as severe if diagnosed with one or more severe 
features [62]. 
a Information is missing from one woman. 
b Maternal BMI in first trimester. Information is missing from four women. 
c Blood pressure from last healthcare visit before delivery. Information is 
missing from two women. 
d Information is missing from 13 women. 
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density. Functional NOD1 activity was confirmed by cytokine response 
in in vitro stimulated decidual and placental explants. 
We present the first large and comprehensive study of cellular NOD1 
expression across the two sites of maternal-fetal interaction at delivery. 
In accordance with our findings, NOD1 expression and functionality 
have been shown in separate and smaller studies and mainly located to 
the syncytiotrophoblast and cytotrophoblasts in placental villi [33,36, 
38] and cells within the decidua [33,34]. Together with reports of first 
trimester NOD1 expression and activation in trophoblasts and placental 
villi [31,35,37] and in the decidua [31,32,39], our data suggest that 
NOD1 mediated inflammation plays a role at the maternal-fetal interface 
throughout pregnancy. The universal expression of NOD1 in all 
trophoblast types at the maternal-fetal interface shown here points to 
importance of NOD1 mediated inflammation in fetal cells with diverse 
biological functions, such as migration, tissue preservation and immu-
nity. This further supports that NOD1 is involved in maternal-fetal 
interaction through the decidual changes in cellular phenotype and 
composition observed in the latter half of pregnancy [51,52], but the 
nature of these changes needs further investigation. 
The NOD1 expression markedly increased with increasing aggrega-
tion of decidual trophoblasts and was particularly strong in the placental 
syncytiotrophoblast layer and underlying cytotrophoblasts. Supportive 
of our findings, first trimester studies show higher levels of NOD1 in 
isolated primary trophoblasts compared to placental tissue [35], and in 
placental villi compared to decidua [31]. The different trophoblast types 
are located at the sites of direct maternal-fetal interaction and the close 
proximity to maternal cells and associated danger signals may facilitate 
the strong NOD1 expression in trophoblasts. 
Preeclampsia was associated with higher density of decidual NOD1 
expression. This may represent one inflammatory mechanism contrib-
uting to the dysregulated immune activation at the maternal-fetal 
interface and the consecutive change in immune cell composition in 
decidua to the more inflammatory phenotype seen in preeclampsia [53, 
54]. Supporting this is that potential NOD1 ligands are produced from 
ER stress and lipid deposits at the maternal-fetal interface, both pro-
cesses that are at play in normal pregnancies [55,56] and elevated in 
preeclampsia [56,57]. Although the underlying placental pathology is 
partly shared in preeclampsia with or without FGR, and normotensive 
Fig. 1. Nucleotide-binding oligomerization domain-containing protein (NOD)1 protein expression and cell types in decidua (A–F) and placenta (G–L) at delivery. 
Representative images of decidual and placental tissue from normal pregnancies at gestational age 40 weeks and 39 weeks, respectively, are shown stained by (A,G) 
hematoxylin erythrosine saffron (HES), (B,H) the trophoblast marker cytokeratin 7 (CK7), (C,I) the endothelium marker CD31, (D,J) the leukocyte marker CD45, (E, 
K) NOD1, and (F,L) negative isotype control for NOD1. Black arrows indicate extravillous trophoblasts, transparent arrows indicate maternal decidual stroma cells, 
arrow heads indicate maternal leukocytes, dashed arrows indicate the syncytiotrophoblast layer and bold arrows indicate cytotrophoblasts. Scale bar 200 μM. 
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pregnancies with FGR [58,59], the maternal systemic inflammatory 
activation is more vigorous in isolated preeclampsia [60,61]. The 
elevated NOD1 expression in the decidua from preeclamptic women 
without FGR may point to significant influences from the systemic 
maternal inflammatory state on the decidua and reflect a stronger 
maternal contribution to the disease. The pronounced systemic inflam-
mation in preeclampsia may augment local inflammatory responses at 
the maternal-fetal interface and vice versa. This interactive inflamma-
tory activation clearly supports the strong correlation found for 
decidual-placental regulation of NOD1 expression associated with pre-
eclampsia. Our findings suggest that NOD1 mediated inflammation in 
normal pregnancies is regulated locally, while it in preeclampsia may be 
speculated that the inflammatory regulation at the two aligned sites of 
the maternal-fetal interface reflects a more widespread and coordinated 
Fig. 2. Protein expression levels of Nucleotide-binding oligomerization domain-containing protein (NOD)1 in decidua and placenta at delivery in normal preg-
nancies. NOD1 expression intensity in normal pregnancies was quantified (A) according to the number of fetal trophoblasts (0%, >0–50% and >50% trophoblasts) in 
decidual tissue (n = 44), and (B) overall in placental villi and specifically in the placental syncytiotrophoblast layer and underlying cytotrophoblasts (n = 13). Data 
were analyzed by a linear mixed model and expression levels are shown as estimated means with standard error of mean. ***P < 0.0001. A.U., arbitrary units. 
Fig. 3. Cytokine response following Nucleotide-binding oligomerization domain-containing protein (NOD)1 stimulation of decidual and placental explants. Explants 
from (A,B) decidua (n = 4) and (C,D) placenta (n = 5) from normal pregnancies at delivery were incubated for 24 h with or without iE-DAP (NOD1-agonist) or iE-lys 
(NOD1-antagonist). Six technical replicates were included for each experimental condition. Release of (A,C) interleukin (IL)-6 and (B,D) IL-8 was measured by ELISA 
and is presented as mean ± standard error of the mean relative to explant weight (mg). Data were analyzed using one-way ANOVA or Kruskal-Wallis with Dunnett’s 
and Dunn’s multiple comparison post-hoc test, respectively. **P < 0.01, ***P < 0.001. 
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inflammation. This important finding results from studying more severe 
phenotypes of preeclampsia. Still, it can be expected that NOD1 medi-
ated inflammation plays a possible coordinated systemic and local role 
at the maternal-fetal interface also in less severe preeclampsia pheno-
types, but this needs to be further investigated. Our results clearly 
highlight the importance of combined understanding of pathological 
processes at the two interconnected sites of the maternal-fetal interface. 
The limitation of analyzing single tissue samples from the decidua and 
placenta was sought to be overcome by investigating large tissue scans 
by a novel automated cellular quantification method. 
This study suggests that activation of NOD1 may be involved in the 
physiological inflammation occurring in pregnancy through mecha-
nisms of cellular communication at the maternal-fetal interface. The 
universal expression of NOD1 by trophoblasts across the two sites of the 
maternal-fetal interface points to a particular role for NOD1 in the 
diverse trophoblast activities. The augmented expression of NOD1 in 
preeclampsia with normal fetal growth and the enhanced decidual- 
placental correlation of NOD1 expression in preeclampsia, suggest 
added involvement and regulation of NOD1 mediated inflammation at 
the maternal-fetal interface in preeclampsia. By combined assessment of 
Fig. 4. Protein expression levels of Nucleotide-binding oligomerization domain-containing protein (NOD)1 in decidua and placenta at delivery in normal preg-
nancies and pregnancies with preeclampsia (PE) with or without fetal growth restriction (FGR). NOD1 expression was quantified as (A,C) NOD1 density and (B,D) 
NOD1 intensity in (A,B) decidual tissue from normal pregnancies (n = 44), PE without FGR (PE-FGR, n = 19) and PE with FGR (PE + FGR, n = 27), and (C,D) 
placental tissue from normal pregnancies (n = 43), PE-FGR (n = 22) and PE + FGR (n = 26). Data were analyzed by a linear regression model. *P < 0.05. A.U., 
arbitrary units. 
Fig. 5. Cellular expression of Nucleotide-binding 
oligomerization domain-containing protein (NOD)1 
related to presence of fetal trophoblasts in decidua at 
delivery. NOD1 expression was quantified and related 
to presence of fetal trophoblasts in third trimester 
decidual tissue from normal pregnancies (n = 44), 
preeclampsia (PE) without fetal growth restriction 
(FGR) (PE-FGR, n = 19) and PE with FGR (PE + FGR, 
n = 27) as indicated. NOD1 expression was signifi-
cantly increased in PE with normal fetal growth when 
compared to normal pregnancies for presence of fetal 
trophoblasts above 48% (vertical line). Data were 
analyzed by a linear mixed model. A.U., arbitrary 
units.   
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both sites of the maternal-fetal interface in normal pregnancies and in 
distinct subtypes of preeclampsia, this work contributes to the under-
standing of underlying inflammatory processes at the maternal-fetal 
interface and how these processes are interconnected with and influ-
enced by the maternal systemic response. Such comprehensive ap-
proaches are needed to establish a solid fundament for biomarker 
selection and identification of treatment strategies for the complex 
pregnancy disorder preeclampsia. 
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